ENTX vs. MGTX, TNYA, SCLX, PSTX, IPSC, ADAP, MOLN, GNFT, MGX, and CADL
Should you be buying Entera Bio stock or one of its competitors? The main competitors of Entera Bio include MeiraGTx (MGTX), Tenaya Therapeutics (TNYA), Scilex (SCLX), Poseida Therapeutics (PSTX), Century Therapeutics (IPSC), Adaptimmune Therapeutics (ADAP), Molecular Partners (MOLN), Genfit (GNFT), Metagenomi (MGX), and Candel Therapeutics (CADL). These companies are all part of the "biological products, except diagnostic" industry.
MeiraGTx (NASDAQ:MGTX) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, community ranking, institutional ownership, dividends and earnings.
In the previous week, Entera Bio had 1 more articles in the media than MeiraGTx. MarketBeat recorded 3 mentions for Entera Bio and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.22 beat Entera Bio's score of 0.93 indicating that Entera Bio is being referred to more favorably in the news media.
MeiraGTx presently has a consensus price target of $26.00, indicating a potential upside of 492.26%. Entera Bio has a consensus price target of $10.00, indicating a potential upside of 383.09%. Given Entera Bio's higher probable upside, analysts plainly believe MeiraGTx is more favorable than Entera Bio.
MeiraGTx has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.
Entera Bio has a net margin of 0.00% compared to Entera Bio's net margin of -651.19%. MeiraGTx's return on equity of -103.40% beat Entera Bio's return on equity.
Entera Bio has lower revenue, but higher earnings than MeiraGTx. Entera Bio is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.
67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 8.4% of MeiraGTx shares are owned by insiders. Comparatively, 8.9% of Entera Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
MeiraGTx received 12 more outperform votes than Entera Bio when rated by MarketBeat users. Likewise, 71.10% of users gave MeiraGTx an outperform vote while only 67.05% of users gave Entera Bio an outperform vote.
Summary
Entera Bio beats MeiraGTx on 9 of the 17 factors compared between the two stocks.
Get Entera Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Entera Bio Competitors List
Related Companies and Tools
